Archive

Neovasc Provides Initial Comments on Lawsuit

NASDAQ, TSX: NVCN VANCOUVER, Sept. 11, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory...

Read More

Neovasc Announces Second Quarter 2018 Financial Results

NASDAQ, TSX: NVCN First implant of a Neovasc Reducer™ in a U.S. patient Reducer Q2, 2018 revenue up 64% over Q2, 2017 and at 108% of Q2, 2018 plan Tiara™ featured in live case at 11th Annual TVT conference Receipt of proceeds of US$13.1 million from exercise of Series...

Read More

Neovasc Announces Publication of Safety and Efficacy Results from REDUCE Study in International Journal of Cardiology

NASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter clinical registry -...

Read More

Neovasc to Present at the 38th Annual Canaccord Genuity Growth Conference

NASDAQ, TSX: NVCN VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that Fred Colen, President and Chief Executive Officer of Neovasc, is scheduled to present...

Read More